Amgen Inc.'s Repatha and Sanofi/Regeneron Pharmaceuticals Inc.'s Praluent are still struggling to get off the ground – but there is hope ahead for the PCSK9 inhibitors in terms of better labeling and better positioning in treatment guidelines for cholesterol reduction due in early September.
PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes
Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but a negative JAMA editorial is another knock on the PCSK9 inhibitor class.
More from New Products
More from Scrip
• By
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
• By
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.